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For more than one hundred years, several treatments against malaria have been proposed but they have
systematically failed, mainly due to the occurrence of drug resistance in part resulting from the exposure
of the parasite to low drug doses. Several factors are behind this problem, including (i) the formidable
barrier imposed by the Plasmodium life cycle with intracellular localization of parasites in hepatocytes
and red blood cells, (ii) the adverse fluidic conditions encountered in the blood circulation that affect the
interaction of molecular components with target cells, and (iii) the unfavorable physicochemical
characteristics of most antimalarial drugs, which have an amphiphilic character and can be widely
distributed into body tissues after administration and rapidly metabolized in the liver. To surpass these
drawbacks, rather than focusing all efforts on discovering new drugs whose efficacy is quickly decreased
by the parasite’s evolution of resistance, the development of effective drug delivery carriers is a promising
strategy. Nanomaterials have been investigated for their capacity to effectively deliver antimalarial drugs
at local doses sufficiently high to kill the parasites and avoid drug resistance evolution, while maintaining
a low overall dose to prevent undesirable toxic side effects. In recent years, several nanostructured
systems such as liposomes, polymeric nanoparticles or dendrimers have been shown to be capable of
improving the efficacy of antimalarial therapies. In this respect, nanomaterials are a promising drug
delivery vehicle and can be used in therapeutic strategies designed to fight the parasite both in humans
and in the mosquito vector of the disease. The chemical analyses of these nanomaterials are essential for
the proposal and development of effective anti-malaria therapies. This review is intended to analyze the
application of nanomaterials to improve the drug efficacy on different stages of the malaria parasites in
both the human and mosquito hosts.
1 Introduction
As defined by the World Health Organization (WHO), malaria is
one of the infectious diseases of poverty (DoP) of global health
importance in tropical and subtropical regions.1 In 2018, 93% of
the malaria cases occurred in the WHO African Region, followed
by 3.4% in the South-East Asian Region, and 2.1% in the Eastern
Mediterranean Region.2 Although the number of infected patients
and deaths caused by malaria has decreased from 251 million
cases and 585 000 deaths in 2010 to 228 million cases and 405 000
deaths in 2018,2 eradication is still beyond reach, and the search
for accessible and effective prevention and curing strategies along
with significant investments is still a need to make it feasible.
In this context, nanoscience and nanotechnology are well
placed to bring innovative solutions to the enormous challenge
of winning the fight against DoP.3 Nanomaterials, which have
been extensively focused on cancer-related biomedical applica-
tions for many years, are being intensively investigated to
implement strategies to prevent and cure malaria, with the
aim of overcoming the problems arising with conventional
therapies.4–6 Furthermore, as a vector borne parasitic disease,
malaria can be faced at several stages of the infection process,
from the mosquito vector to the infected erythrocytes, and
these constitute different challenges to generate novel antima-
larial strategies. Most efforts are addressed towards targeted
drug-delivery systems, mostly including known antimalarial
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drugs. When developing anti-infective therapeutics, two essen-
tial objectives have to be fulfilled: delivering sufficiently high
local doses that will rapidly eliminate the pathogen without
allowing for it to evolve resistance, and doing so with overall
doses sufficiently low so not to have side effects on the human
host. Both goals can be simultaneously achieved through
targeted drug delivery strategies that make use of nanocarriers
(NCs).7,8 Many NCs have the capacity to encapsulate different
types of drugs and of being functionalized with ligands
targeting them to the desired cell type. In addition, if the NCs
are loaded with large numbers of drug molecules to be delivered
together, their antiparasitic effect will be potentiated and they
will have a higher chance to quickly kill the infectious agent.
NCs can be made having long shelf half-lives, low unspecific
toxicity, large drug loading capacity, extended blood circulation
times and safe elimination mechanisms.
In addition to therapeutic applications, nanomaterials could
be ideally adapted to the development of new prevention
strategies. Considering the difficulties in obtaining an efficient
malaria vaccine,9 NCs are suited to be functionalized with
several antigens, which might dramatically boost the prospects
of obtaining a stronger immune response than with the current
classical vaccination approaches.
Mosquito vector control constitutes an essential issue for
malaria prevention since it can be highly effective to prevent
transmission. The use of nets treated with insecticides and
indoor spraying are the most frequent protection measures.
However, the mosquito can be also reached through nano-
materials. The antimicrobial activity of metals such as silver, gold
or platinum can be enhanced in biosynthesized nanostructured
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This review collects the research done on different types of
nanomaterials which can be adapted to implement promising
antimalarial tools with therapeutic or prophylactic roles. Before
discussing the most relevant results in the literature, this
review includes sections dedicated to the main characteristics
of malaria infection and those challenges that nanomaterials
face to constitute effective weapons against malaria.
2 Malaria
Malaria is a parasitic disease caused by Plasmodium spp. Among
the more than 120 species in this genus, five of them (Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium
ovale, and Plasmodium knowlesi) cause malaria in humans,
P. falciparum and P. vivax being those involved in global
malaria.12,13 P. falciparum is the species responsible for the most
severe and potentially fatal form of malaria, whereas P. vivax has
dormant liver stage parasites (hypnozoites) that can trigger a fully-
fledged infection after months or even years remaining in a
quiescent intrahepatocytic state.4
Plasmodium is an intracellular parasite with a complex life
cycle shared between the human host and a mosquito vector
from the Anopheles genus. When an infected mosquito bites a
human, Plasmodium sporozoites (Fig. 1.1) that reside in the
salivary glands are released into the blood stream and reach the
liver, where they infect hepatocytes and multiply inside them
(Fig. 1.2). Subsequently, parasite forms called merozoites are
released into the blood, where in less than a minute14 they
invade red blood cells (RBCs) and mature inside them. Ring
stages grow into trophozoites as they feed on hemoglobin, and
later divide their nuclei to form schizonts, from which the next
generation of merozoites egresses to reinvade new RBCs, thus
perpetuating the so-called intraerythrocytic cycle (Fig. 1.3).
These stages of the parasite are responsible for all malaria
symptoms, such as periodic fevers resulting from the immune
response to the parasite,15 or more severe conditions such as
placental malaria16 or capillary occlusion,17 which are derived
from parasite sequestration in capillaries18 and from a phe-
nomenon called rosetting, i.e. the adhesion between parasi-
tized RBCs (pRBCs) and naı̈ve RBCs to form cell aggregates
termed rosettes.
A small number of pRBCs differentiate in each cycle towards
the formation of gametocytes (Fig. 1.4),19 sexual forms of the
parasite that sequester in the bone marrow until they mature
and return to the circulation. When removed with a mosquito
blood meal, gametocytes egress from the pRBC and become
gametes. Fertilization produces a zygote (Fig. 1.5) that becomes
a motile ookinete, which leaves the blood bolus to reach and
cross the mosquito midgut endothelium, where it differentiates
into an oocyst (Fig. 1.6) that grows to spawn sporozoites. These
close the cycle by travelling through the haemolymph towards
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the mosquito salivary glands, where they are ready for new
inoculation into a human host (Fig. 1.1).
3 Challenges for drug delivery
3.1 Drugs
There is currently a large variety of antimalarial drugs (Fig. 2),
but their application is often limited due to the development of
resistance. In this regard, the WHO encourages the use of
combination therapy, where two or more medicines with dif-
ferent mechanisms of action are used together, which helps to
prevent or delay drug resistances.20 In this section, we present
the most commonly used antimalarial drugs and briefly
describe their distinct characteristics as well as precise anti-
plasmodial use.
Quinine (QN) was the first purified compound used to treat
malaria and has been the most common and effective option to
date.21 This drug is active against all Plasmodium spp. schizonts
and the gametocytes of P. vivax, P. malariae and P. ovale but not
against those of P. falciparum.20,22 Due to its reported resistance,
QN is not currently used as the leading treatment but it is still
employed for severe malaria.20,21 QN is also recommended
together with clindamycin in the treatment of uncomplicated
malaria during the first trimester of pregnancy.20,23 This drug
belongs to the aryl amino alcohol pharmacophore-type like
lumefantrine, mefloquine, halofantrine or quinidine. Lumefan-
trine is another widely used drug, which is not administered alone
but in combination with artemether (an artemisinin-derivative) to
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Fig. 1 Life cycle of Plasmodium. In a mosquito bite, sporozoites are
injected (1), invade hepatocytes and divide inside them (2). Then mero-
zoites are released into the blood and invade erythrocytes, growing and
reinvading new RBCs in the intraerythrocytic cycle (3). Some merozoites
differentiate into gametocytes (4), which are taken in another mosquito
blood meal, and egress from the pRBC, forming the gametes that fuse into
the zygote (5). The zygote develops into an ookinete that traverses the
mosquito midgut to form an oocyst (6) that will grow until releasing the
infective sporozoites. Image courtesy of the National Institute of Allergy
and Infectious Diseases (https://www.niaid.nih.gov/diseases-conditions/
malaria-parasite).
Fig. 2 Some antimalarial drugs discussed in this review.
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treat uncomplicated P. falciparum malaria in multiple doses.20
Due to its high lipophilicity, it requires being taken up within a
fatty diet, which can represent a problem due to the difficulty in
poor populations of having continuous access to such a meal.20
Mefloquine is commonly used as a chemoprophylactic for all
types of malaria and in combination with artesunate (ATS) to treat
uncomplicated malaria.20
Other common active compounds against malaria include
the 4-aminoquinolines (e.g. chloroquine, quinacrine, hydroxy-
chloroquine, piperaquine, and amodiaquine) and the 8-amino-
quinolines (primaquine, tafenoquine, and pamaquine). Chloro-
quine (CQ) is well absorbed from the gastrointestinal tract after
oral administration. This drug is used to treat uncomplicated
malaria caused by P. vivax, P. malariae and P. ovale in areas
without CQ resistance.20 Primaquine (PQ) is the most remark-
able drug belonging to the 8-aminoquinolines. It shows activity
against P. vivax and P. ovale hypnozoites and it is generally
administered together with artemisinin derivatives or CQ.20
Like other 8-aminoquinoline-type drugs, primaquine can entail
risk for patients with glucose-6-phosphate dehydrogenase
deficiency, which is unfortunately very common in malaria-
endemic areas.24
On the other hand, ATS, artemether, arteether and dihydroar-
temisinin are the most common artemisinin derivatives employed
to treat malaria through artemisinin-based combination therapy
(ACT).21 The most frequent ACT drug combinations to treat
uncomplicated malaria are artemether/lumefantrine, ATS/
amodiaquine, dihydroartemisinin/piperaquine, ATS/mefloquine
and ATS/sulfadoxine-pyrimethamine.25 Atovaquone/proguanil is
a non-artemisinin-based combination therapy that is commonly
employed for the prophylaxis of malaria and can be also used to
treat CQ-resistant malaria.20,21
3.2 Antimalarial drug distribution
As the erythrocytic stage is responsible for all symptoms and
pathologies of malaria, it is an obvious target for the adminis-
tration of drugs.26 The bioavailability of antiplasmodial drugs
is highly dependent on the administration route, the parenteral
route being used for severe malaria, while oral delivery is
the optimal strategy for uncomplicated malaria in order to
maximize patient adherence to treatment. Some drugs like
amodiaquine27 and all artemisinin derivatives except ATS28
have poor oral bioavailability, with below 35% of the ingested
drug reaching the blood stream for most of them, thus requiring
high dosages that could result in toxic side effects.
A second challenge for proper treatment is presented by the
pharmacokinetic profile of antimalarial compounds, which has
led to the implementation of combination therapies where, as
explained above, two drugs are delivered together, one of them
being usually an artemisinin derivative. In general, artemisinin
derivatives have short half-lives (t1/2)
29,30 and therefore the
accompanying drug is usually long-lived (t1/2 4 4 days) in order
to achieve complete clearance of the parasite. This approach is,
however, a matter of debate, because the time during which one
of the drugs is present might be long enough to stimulate
resistance evolution.31 Although CQ has an excellent absorption
and circulation time profile,32 its widespread use in the past
triggered the emergence of resistance.33 As a result, CQ is
not widely used as first line treatment anymore, being only
recommended in areas where resistances are not described in
non-falciparum malaria.34
Antimalarials targeting the intraerythrocytic cycle have to
face the challenge of RBC penetration. Mature erythrocytes do
not endocyte,35 and drugs have to be passively absorbed to
penetrate them. Although it is possible to efficiently load large
amounts of drugs on RBCs ex vivo, it requires harsh manipula-
tion such as hypotonic conditions.36 Drugs targeting RBCs
should be hydrophobic to enhance their penetrability (the
front-line drug artemisinin and its derivatives fulfill this
requirement37), although hydrophobicity results in poor pharma-
cokinetics and off-target delivery, leading to accumulation in
non-targeted tissues or interaction with plasma proteins.28,29
Loading drugs into RBCs and using these as vascular carriers
is an attractive alternative because these cells have a large life
span in the blood (of up to 120 days) and a large size, which
prolongs the circulation time and permits the encapsulation of
large amounts of drugs. Erythrocyte drug transporters limit
extravasation, in addition to being biocompatible and safely
removed from the body through natural mechanisms.38–40
As shown by Wilson et al., RBCs pretreated with the antimalar-
ials halofantrine, lumefantrine, piperaquine, amodiaquine and
mefloquine retained them inside, inhibiting the growth of the
parasites that were invading drug-containing RBCs.38
3.3 Drugs reaching Plasmodium
Targeting Plasmodium in its liver phase represents an attractive
prophylactic approach that would prevent the progress of the
disease and its ensuing symptoms and disability caused by
erythrocytic stages. Moreover, the administration of antimalarial
drugs specifically to the liver could also be useful for P. vivax
therapy. However, PQ is the only approved drug for hypnozoites,
with the drawbacks that were discussed in Section 3.1.
Administration to Plasmodium early erythrocytic stages
would be an interesting strategy to allow drugs a longer time
to eliminate the parasite before it completes its intraerythrocy-
tic development. However, delivering active compounds to
RBCs infected with Plasmodium early stages is a challenging
task, because the permeability of pRBCs to drugs remains low
until ca. six hours after invasion.40,41
To reach their molecular targets inside pRBCs, antimalarial
drugs must cross at least 3 membranes (the erythrocyte
membrane, the parasitophorous vacuole and the parasite
membrane),42 plus one extra lipid bilayer for those compounds
having their target inside organelles such as the food vacuole or
the apicoplast. Lipophilic drugs are able to cross these mem-
branes through passive diffusion, whereas other compounds
are carried inside the parasite by available channels or
transporters.42 During Plasmodium intraerythrocytic infection
and maturation, significant alterations in the structural and
functional characteristics of RBCs are observed.43,44 Namely,
Plasmodium changes the lipid and protein composition of the
host cell plasma membrane in order to take up nutrients from
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the blood circulation, dispose of metabolic waste, and create and
maintain electrochemical ion gradients.26,44 Around 10 to 20 h
post-invasion, these alterations result in the formation of new
permeation pathways, which allow the entry into parasitized
RBCs of particles up to diameters of 70 nm.26,44 One transporter
that is exported by the parasite to the pRBC membrane is the
plasmodial surface anion channel, which contributes to nutrient
acquisition for the intracellular parasites.45 Variation or differ-
ences in expression of this channel can be a source of potential
resistances to the drugs relying on it.46–48
For those drugs able to cross the erythrocyte membrane,
further penetration through the pasaritophorous vacuole or
parasite plasma membranes seems to occur with more facility,
as both have high capacity for permeating many solutes,42
possibly to facilitate intake of nutrients into the parasite.
Penetration and a long residence time in certain target orga-
nelles are also important for several drugs to exert their anti-
parasitic action. In the case of CQ, the main resistance
mechanism consists of increasing drug efflux from the diges-
tive vacuole,49 where CQ blocks the heme detoxification
pathway.50 Mutations or gene duplications in transporter
proteins can produce resistance to quinolines.49,51–53 Other
biological features of Plasmodium can significantly reduce the
drug amounts reaching target cells, thus favoring the evolution
of resistance. In the murine malaria model Plasmodium berghei,
spleen-sequestered pRBCs were less sensitive to artemisinin,54
likely because the limited diffusion of drugs into the organ
resulted in final doses reaching the parasite that were much
smaller than those found in the blood circulation.
4 Nanomaterials against malaria
As discussed in the following sections, nanomaterials and
nanotechnology offer good opportunities for the development
of customized nanocarriers capable of trapping antimalarial
drugs as well as exerting targeted delivery. We include below
several subsections in which antimalarial nanomaterials of
different nature are discussed. Namely, nanocarriers built with
lipids, polymers and dendrimers as well as inorganic NPs are
presented. In the final subsection, we describe some other
molecular platforms that do not belong to the previous cate-
gories but also display interesting potential for innovative
antimalarial strategies.
4.1 Liposomes
Liposomes are artificial lipid bilayer vesicles containing an aqu-
eous core formed by the self-assembly of phospholipids in
aqueous media.4,55–57 Since their description in 1965, they have
been extensively and successfully used as a drug delivery system.
Due to their dual hydrophilic/hydrophobic nature, they can
encapsulate water-soluble drugs in the aqueous core and lipo-
philic compounds in the phospholipid bilayer.4,57 Liposomes are
versatile NCs with diverse properties depending on the size,
phospholipid composition (Fig. 3), surface charge, and functio-
nalization with diverse ligands.58,59 This versatility permits
modulating their structure to protect drugs from chemical degra-
dation, increase their solubility, prolong and sustain drug
release, reduce toxicity and target cells specifically.60–62
Liposomes have been successfully administered by parent-
eral routes, but their oral administration is hampered by
several obstacles such as instability in the gastrointestinal tract
and difficulties in crossing biomembranes. By modifying the
compositions of the lipid bilayers and adding polymers or
certain ligands, both the stability and permeability of lipo-
somes can be significantly improved for oral drug delivery.63
For instance, Coma-Cros et al. used the anionic copolymer
Eudragits S100 to assemble liposomes incorporating curcumin
and containing either hyaluronan (Eudragit-hyaluronan lipo-
somes) or the water-soluble dextrin Nutrioses FM06 (Eudragit-
nutriosomes). As a result, curcumin incorporated into Eudragit-
nutriosomes enhanced its antimalarial activity upon oral
administration to Plasmodium yoelii-infected mice. Eudragit-
nutriosomes presented better performance than Eudragit-
hyaluronan liposomes due to the greater stability of the former,
as shown by the vesicle behavior in gastrointestinal fluids.64
Several studies have tried to target liposomes encapsulating
PQ to the liver stage of malaria.65 In P. berghei infections in
Fig. 3 Chemical structure of some phospholipids used in liposome for-
mulation for malaria therapy. 1,2-Dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-dis
tearoyl-sn-glycero-3-phosphocholine (DSPC), L-a-phosphatidylcholines
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mice, liposomes could decrease the toxicity of parenteral PQ
delivery, which allowed for the administration of higher doses
and resulted in the cure of the animals following a single
intravenous injection.66 Tissue distribution studies demon-
strated that PQ encapsulated in liposomes accumulated mainly
in the liver and spleen and not so much in the kidneys, lungs,
heart, or brain, being eliminated more slowly than its
free counterparts.67,68 Although peptide- and amino acid-
conjugated derivatives of PQ encapsulated in liposomes did
not increase the therapeutic effect in comparison to free PQ,66
they presented a reduction of toxicity.68 In another study,
liposomes loaded with antimalarial drugs (especially PQ) were
engineered to contain a galactosyl glycolipid that specifically
targeted a galactose-binding lectin in hepatocytes. These experi-
ments showed a remarkable phenomenon: drug-free liposomes
had a curative effect on sporozoite-induced murine malaria,
likely due to the competition of liposomes and sporozoites for
the same receptor.69 In addition, considering the reduced doses
of PQ required to achieve a curative effect, it was estimated that
the efficacy of PQ was enhanced more than 46 000 times by
its encapsulation into liposomes containing the galactosyl
glycolipid.70
To specifically target the liver in vivo, Longmuir et al. for-
mulated a liposome bearing a 19-amino acid sequence present
at the surface of the P. berghei circumsporozoite protein. This
liposome successfully reached the liver following intravenous
administration in mice.71 Despite these promising results,
liver-targeted-liposomes have not progressed towards a strategy
to fight malaria, probably because of the lack of sufficiently
specific markers for Plasmodium-infected hepatocytes.43 As a
consequence, most current studies using liposomes to deliver
antimalarial drugs target the erythrocytic stage.
Essentially, liposomes can be developed to deliver drugs
to the pathogen’s erythrocytic forms at three different times:
(i) before parasite infection, (ii) to RBCs infected with Plasmo-
dium early stages, and (iii) to RBCs infected with Plasmodium
late stages. The administration of a drug for each of these
phases has its own advantages and challenges. Regardless of
the time when liposomes will deliver the drug, the lack of
endocytic processes in RBCs is one of the main obstacles to be
dealt with. In a proof of concept study, quantum dots encapsu-
lated in liposomes allowed the visualization of a homogeneous
distribution of liposome content within P. falciparum-infected
RBCs. This indicated that the liposomal cargo entered the cell
through fusion of the liposome bilayer with the cell plasma
membrane.72 It has been reported that the fusion of liposomes
with mammalian cells is significantly dependent on the lipid
composition and fluidity of the liposome membrane.44
For instance, the efficacy of stearylamine in inhibiting the
growth of P. falciparum was reduced when incorporated in
sphingomyelin liposomes compared to either egg phosphati-
dylcholine (Egg-PC) or soy phosphatidylcholine (Soy-PC)
liposomes. This probably occurred due to reduced fusion/
interaction of pRBCs with rigid sphingomyelin-containing lipo-
somes compared to fluid Egg-PC or Soy-PC liposomes.44 Thus,
to favor fusion events, it is advisable to formulate liposomes
with relatively fluid lipid bilayers, although this incurs the risk
of leaking for small drugs encapsulated in the liposomal
aqueous core. On the other hand, liposomes formulated with
saturated lipids retain drugs better because they have less fluid
bilayers, but at the cost of decreased membrane merging with
target cells.39 In both cases, the amount of delivered drug will
get reduced, and a balance must be found to limit drug leakage
while allowing lipid bilayer fusion events.
Antibodies have been successfully used to target pRBCs.43,73–76
Antibody-targeted liposomes containing on their surface F(ab0)2
fragments of a mouse monoclonal antibody raised against
P. berghei-infected mouse erythrocytes significantly increased
the therapeutic efficacy of CQ, showing that target-specific lipo-
somes can cure CQ-resistant malarial infections.73 Urbán et al.
also observed an improvement of up to tenfold in the therapeutic
effect of CQ when delivered inside liposomes covalently functio-
nalized with oriented, specific half-antibodies against P. falci-
parum late form-infected RBCs.43 Further studies showed that
this same targeted liposome similarly improved the in vitro
efficacy of fosmidomycin, another antimalarial drug.74 Immuno-
liposomes formulated using as a targeting molecule a polyclonal
antibody against the NTS-DBL1a N-terminal domain of P. falci-
parum erythrocyte membrane protein 1 (PfEMP1) and encapsu-
lating lumefantrine were also used to specifically recognize and
disrupt rosettes while simultaneously eliminating those pRBCs
forming them.76 As shown by these studies, antibody-
functionalized liposomes can discriminate pRBCs from non-
infected RBCs and specifically deliver antimalarial drugs to
pRBCs. However, some issues limit the use of antibodies as
targeting molecules in antimalarial therapy, such as the elevated
cost of production,77 the high immunogenicity unless genetically
engineered humanized forms are used, and the potential
decrease in targeting efficiency due to the variability of Plasmo-
dium proteins exposed on pRBC surfaces.26
Past research has paid little attention to the development of
liposomes to deliver a drug to RBCs before Plasmodium infec-
tion; however, this strategy could represent an interesting
prophylactic approach that deserves further study. Moles
et al. developed an immunoliposome bearing antibodies
against the RBC surface protein glycophorin A that targeted
all RBCs, both naı̈ve and Plasmodium-infected.39 In addition to
targeting the parasite, this approach permitted loading of drugs
into RBCs prior to infection. To improve the targeting proper-
ties, a lipid bearing a 2 kDa polyethylene glycol (PEG) linker
terminated with a maleimide group (Mal) was included in the
liposome formulation aiming to facilitate antigen access to
targeting antibodies (Ab) and to enhance the coupling reaction
sterically hindered in the original immunoliposome by the
polar heads of surrounding lipids. Three types of liposomes
(LP) were designed and the linker was used for the oriented
binding of half-antibodies through their free thiols (LP-PEG-
Mal-Ab) or of whole antibodies through their carbohydrate
(CHO) moieties present in antibody Fc regions (LP-PEG-Mal-
CHO-Ab), and for non-oriented binding through primary
amino groups on Ab amino acid residues (LP-PEG-Mal-NH2-Ab).
The type of binding influenced the cell targeting efficiency
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(LP-PEG-Mal-NH2-Ab c LP-PEG-Mal-CHO-Ab c LP-PEG-Mal-Ab).
39
These glycophorin A-targeted liposomes loaded with CQ were
highly efficient in transferring the drug into RBCs, as demon-
strated by a complete inhibition of in vitro parasite growth
after only 15 min of incubation with the immunoliposomized
drug, whereas after the same time an equal amount of free CQ
had no observable effect on the parasite viability. In this
scenario, the parasite encountered the drug immediately after
entering the host cell, which drastically compromised its
survival capacity.39
Although the administration of active compounds to RBCs is
a promising prophylactic strategy, some requirements have to
be considered, including (i) determination of a maximum
immunoliposome concentration in vivo to avoid RBC
agglutination,39 (ii) restriction to drugs that do not interfere
with RBC physiology,78 and (iii) use of liposome formulations
that will merge with the RBC before the cell is removed by the
spleen due to alterations induced by liposomes adsorbed on its
surface.39
Since only after around 24 h post-invasion will Plasmodium
export a substantial number of receptors and transporters to
the host cell plasma membrane, the design of liposomes
specifically targeted to early blood stages has remained remark-
ably elusive.40 Most published studies report the development
of liposomes for delivering an active compound to late parasite
stages,26,39,43,60,73–76,79–84 when significant alterations in the
structural and functional characteristics of RBCs are
observed.43,44 These liposomes have been formulated to deliver
a high amount of drug to the targeted site to compensate for
the short time available to kill the parasite before its egress.
Different strategies can be used alone or in combination to
guarantee an optimal therapeutic drug dose (as depicted in
Fig. 4), including approaches to improve the encapsulation
efficiency,39,75,83 to efficiently target RBCs infected with Plas-
modium late stages26,43,73–76,84 and to increase the circulation
time of liposomes.80–82 In addition, combination therapies
contemplating the simultaneous administration of two or more
active compounds have also been proposed.60,79 The encapsu-
lation efficiency in liposomes of many antimalarial drugs can
be increased using active loading techniques based on pH
gradients.39,75,83 Drugs with amphiphilic nature such as CQ
and PQ, which depending on the solution pH present different
degrees of protonation, can be efficiently encapsulated using a
pH gradient.75,83 The majority of antimalarial drugs under
development are lipophilic with poor plasma solubility and large
biodistribution volumes and, consequently, with low accumula-
tion in RBCs.57,75 Active encapsulation in liposomes using a
citrate-buffered pH gradient allowed for the stable incorporation
of hydrophobic drugs containing weakly basic ionizable moieties,
which accumulate in the inner liposome membrane leaflet. Aryl
amino alcohol- and 4-aminoquinoline-type drugs were efficiently
delivered to P. falciparum-infected RBCs upon encapsulation into
liposomes targeting all RBCs, inhibiting parasite growth in vitro
and exhibiting considerable improvements in drug activity when
compared to the free administered drug after only 15 min of
exposure to P. falciparum cultures.75
As interesting alternatives to antibody-mediated targeting,
certain glycosaminoglycans like heparin, heparan sulfate and
chondroitin sulfate84 are being recognized as one of the main
pRBC-binding molecules.26 Heparin bound to liposomes has
dual activity as a pRBC targeting molecule acting mainly on
trophozoites of some PfEMP1-expressing lines,85 and on schi-
zont stages,86 and as an antimalarial drug it blocks merozoite
invasion of erythrocytes.87 In addition, heparin is significantly
less expensive to obtain than monoclonal antibodies, resulting
in heparin-liposomes having a cost about ten times lower than
immunoliposomes of similar targeting activity.84 In addition,
and most importantly, no resistance to heparin as an antima-
larial drug has been described so far.87 Furthermore, it has
been shown that the anticoagulant activity of heparin when
covalently bound to liposomes was substantially reduced.84
Heparin used at non-anticoagulating concentrations electrosta-
tically adsorbed onto positively charged liposomes enhanced
threefold the activity of encapsulated PQ in in vitro P. falciparum
cultures.
Heparin-related polysaccharides such as heparan sulfate88,89
and chondroitin sulfate90 could also be used as targeting
molecules and, compared with heparin, they have the advan-
tage of having a much lower anticoagulant activity.84 Marques
et al. used single-molecule force spectroscopy to measure the
binding forces between chondroitin 4-sulfate and pRBCs or
non-infected RBCs deposited on poly-L-lysine-coated glass
slides.84 Although specificity of adhesion of these polysacchar-
ides to pRBCs has been observed, challenges related to the
Fig. 4 Schematic representation of liposomes formulated using different
strategies aiming at improving the therapeutic efficacy of encapsulated
drugs. Conventional liposomes are formed by phospholipids and cholesterol
and can encapsulate hydrophilic drugs in their aqueous core and hydro-
phobic compounds in their phospholipid bilayer. Active encapsulating lipo-
somes hold a pH gradient that can improve the loading of drugs with
amphiphilic nature, which, depending on the pH, are found in their protonated
or deprotonated forms. Ligand-targeted liposomes are developed using specific
pRBC ligands such as antibodies or heparin and promote the delivery of high
drug doses with few side effects. Long-circulating liposomes can be formulated
by modifying the surface of liposomes with PEG to enhance the blood
residence time.
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attachment of a ligand on the liposome surface in a reprodu-
cible manner under good manufacturing practice conditions
should be considered and stability requirements have to be
optimized.91
Long-circulating liposomes can considerably enhance the
blood residence time, improve the release profile of the drug at
the site of infection, and facilitate a better interaction with
infected RBCs, resulting in the inhibition of parasite growth to
a higher extent.4,80 It has been shown that the interaction of
PEG-grafted liposomes with pRBCs depends on the density of
the polymer and the optimal chain length.80 Rajendram et al.
demonstrated that the circulation life of the drug monensin
can be modulated using PEG-functionalized lipids and lipo-
somes modified with different densities of distearoyl
phosphatidylethanolaminemethoxy-PEG 2000 (DSPE-mPEG-
2000), which enhanced the antimalarial efficacy of liposomal
formulations compared with that of free monensin. This study
also reported that the coadministration of stearylamine, mon-
ensin, and artemisinin with 5% DSPE-mPEG-2000 could com-
pletely eliminate the parasite burden.80 It has also been shown
that the antiplasmodial activity of stearylamine in liposomes
has the maximum effect when delivered through Soy-PC lipo-
somes. The inhibition of parasite growth was regulated by the
chain length of the alkyl group and the density of stearylamine
in liposomes. In addition, the incorporation of either choles-
terol or DSPE-mPEG-2000 in Soy-PC-stearylamine liposomes
improved their efficacy.44 Liposomes were also used to improve
the short half-life and poor bioavailability of artemisinin81 and
its derivatives, such as ATS.82 Artemisinin loaded in conven-
tional and PEG-containing liposomes showed a much longer
blood circulation time than free artemisinin, being detectable 3
and 24 h after administration, respectively, while free artemi-
sinin was rapidly cleared from the plasma and barely detected
1 h after administration.81 Hydrophobic ATS was conjugated
with hydrophilic glycerophosphorylcholine as a linker to
synthesize an ATS-based dimeric conjugate. The conjugate
was assembled into liposomes with a high drug loading of
77.6%, exhibiting a longer blood half-life and superior in vitro
antimalarial activity compared to free ATS and conventional
ATS-loaded liposomes, without causing hemolysis.82
The simultaneous administration of several drugs usually
improves their separate antimalarial effects,60,92 and lipo-
somes, due to their structure, are ideally suited for such
combination therapies at the nanoscale.77,84 Curcuminoids,
which are poorly water-soluble compounds with promising
antimalarial activity, were loaded into liposomes for intrave-
nous administration and combined with the intramuscular
administration of a/b artemether, which is known to have a
short half-life in the body. This combination therapy was able
not only to cure P. berghei-infected mice but also prevented
recrudescence.60 Nevertheless, combined drugs exhibit differ-
ent pharmacokinetic profiles and are often eliminated from the
circulation at different rates, which decreases the treatment
efficacy. However, if drugs are delivered encapsulated together,
they will be removed from the organism simultaneously with
their carrier, thus sustaining constant relative ratios
throughout the treatment. Based on this concept, a glycophorin
A-targeted immuno-PEG-liposome was formulated to encapsu-
late the hydrophilic antimalarial pyronaridine in its aqueous
core and the lipophilic compounds domiphen bromide or
atovaquone in its lipid bilayer. When tested in in vitro
P. falciparum cultures, this strategy offered antiparasitic activ-
ities significantly higher than when the drugs were adminis-
tered together in their free forms.79
Despite the considerable therapeutic advantages of lipo-
somes, their clinical translation to antimalarial treatments
has not progressed as quickly as the encouraging positive
preliminary results predicted. The main issues behind this
delay are pharmaceutical manufacturing limitations, govern-
ment regulations and intellectual property.93
4.2 Polymers
This section includes relevant studies reported in recent years
focused on polymeric nanostructures developed for drug deliv-
ery systems, polymer-based prodrugs and also prophylactic
tools.94 The last sub-section is devoted to dendrimers as a
unique family of hyperbranched polymers with special features
for drug conjugation.
4.2.1 Polymeric NCs for encapsulation and covalent con-
jugation of drugs. A group of cationic (AGMA1 and ISA1) and
anionic (ISA23) polyamidoamines containing tert-amine, car-
boxyl, guanidine and/or hydroxyl groups (Fig. 5) have been
studied by Fernàndez-Busquets et al.95 for the encapsulation
and systemic delivery of CQ and PQ. In addition, these struc-
tures together with a cationic poly(amidoamino acid) containing
L-arginine units, ARGO7, were thoroughly studied by the
same group for the oral administration of CQ.96 Further
traceability studies of the empty polyamidoamines labeled with
fluorescein and orally administered to female Anopheles
Fig. 5 Chemical structures of AGMA1, ISA23, ISA1 and ARGO7.95,96
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gambiae mosquitoes postulated these polymeric platforms as
good NCs to directly target Plasmodium in the mosquito
vector.97
Biodegradable synthetic polymers such as poly(D,L-lactic-co-
glycolic acid) (PLGA), polyalkylcyanoacrylates or poly(D,L-lactic
acid) have been broadly used to prepare polymeric NPs.6,98
Some studies with PLGA NPs included the synergistic
co-delivery of CQ and the antibiotic azithromycin99 (the most
potent antimalarial macrolide widely studied in combination
with other antimalarial drugs to improve their efficacy100) and
the co-encapsulation of ATS and curcumin101 as promising
combination therapies for malaria.
Another possibility explored is the use of nanocapsules
composed of an oil core surrounded by a polymeric membrane.
One example is found in the work of Haas et al., where poly(e-
caprolactone) (PCL) and polysorbate 80 (also called Tween 80)
nanocapsules were used to deliver QN.102 Similarly, the anti-
malarial halofantrine was encapsulated into PCL nanocapsules,
which resulted in an improvement of the cardiovascular para-
meters frequently altered by this drug.103 In this line, Velasques
and co-workers developed polysorbate 80-coated PCL nanocap-
sules to co-encapsulate QN and curcumin, increasing the
efficacy against P. falciparum at the same time that the cyto-
toxicity was reduced.104
A series of three hydroxypropylmethylcellulose (HPMC) poly-
mers with different grades of acetyl (A) and succinyl (S) func-
tionalization (HPMC-AS, Fig. 6), and the amphiphilic block
copolymer PCL-block-poly(ethylene glycol) (PCL-b-PEG) were
tested to improve the oral bioavailability of the synthetic
antimalarial artefenomel mesylate (or OZ439). Specifically, the
drug was coupled with an anionic species to form a hydro-
phobic ion pair complex,105 in an encapsulation process that
was done through a scalable and cheap method called flash
nano precipitation. Polymers with higher succinate contents
displayed larger negative charge, whereas the introduction of
acetyl moieties resulted in more hydrophobicity. Polymers with
larger percentages of either succinate or acetyl did not show
enhanced encapsulation efficiency, suggesting that both hydro-
phobic and ionic interactions (succinate groups on HPMC-AS)
were required for stability. This was also demonstrated by
the lack of stability provided by the non-charged amphiphilic
PCL-b-PEG. Release experiments were done mimicking oral
administration and in vivo conditions. These polymer-based
NPs exhibited a sustained OZ439 release profile and signifi-
cantly higher drug bioavailability compared to that of the
unencapsulated drug.
Antisense oligodeoxynucleotides (ODN) represent an alter-
native to traditional antimalarial drugs. However, their low
stability in plasma can hamper their therapeutic function.
The potential of the positively charged chitosan polymer to
stabilize ODN through the formation of polyplexes was
explored by Foger et al., enabling ODN to show optimal inter-
ference with the expression of Plasmodium topoisomerase II, an
enzyme necessary for parasite division after invasion of human
erythrocytes.106 Further studies employed this natural amino-
glucopyran to covalently conjugate artemisinin (Fig. 7), obtaining
more soluble derivatives.107 This original strategy consisting of
the covalent bonding of the drug to a polymer carrier was
proposed in 1975 by Helmut Ringsdorf.108 Generally, an enzyme
or pH-sensitive linker is employed to enable drug release once in
the intracellular environment.24
Despite the scarce exploration of this strategy in the field of
infectious diseases caused by a parasite, its successful use for
leishmaniasis treatment109,110 encouraged its application to
malaria since both pathologies share many features.24 PQ
represents the most widely studied antimalarial drug within
the polymer–drug conjugation approach. Already in 1986, PQ
modified with a pendant cysteine group was linked through a
disulfide bond to a protein carrier containing (pyridyldithio)-
propionate groups.111 More recently, PQ was also conjugated to
poly-g-glutamic acid (PGA) modified with a synthetic trivalent
glyco-ligand (TriGalNAc) through an amide linkage, obtaining a
TriGalNAc-PGA-PQ conjugate.112
This covalent approach has been also used for the conjuga-
tion of more than one drug onto the same polymer, a desirable
Fig. 6 General reaction scheme to convert HPMC polymers to HPMC-AS
through the addition of acetyl and succinyl groups.105 Fig. 7 Synthesis of chitosan-artemisinin derivatives.107
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strategy for combination therapy. An example is found in
Kumar and co-workers’ poly(organophosphazenes), an inorganic
polymer designed as a nanocarrier for the co-delivery of PQ
and dihydroartemisinin.113,114 Firstly, the polymeric backbone
of poly(dichlorophosphazene) was functionalized with various
substituents like isopropyl alcohol, 4-hydroxyacetanilide,
4-hydroxybenzaldehyde and ethyl 4-aminobenzoate, providing a
wide variety of physicochemical properties. Then, the remaining
unsubstituted polymer backbone was substituted stepwise with
the two drugs to provide the polymer-linked combined antima-
larial drug conjugates. All the prepared NPs showed negative
surface charge (between 21 and 32 mV) and a diameter
between 128 and 179 nm, and their antimalarial activity was
improved compared to the standard drug combination.
Polymer NCs have been also investigated to improve the
action of the antimalarial drug atovaquone, creating long-acting
injectable formulations. Bakshi et al. prepared a library of solid
drug NPs containing atovaquone and a binary combination of
surfactant and polymer, including e.g. poly(ethylene oxide)80-
block-poly(propylene oxide)27-block-poly(ethylene oxide)80 (Pluro-
nic F68), poly(vinylpyrrolidone) (PVP K30), HPMC, polyvinyl
alcohol (PVA), and PEG.115 The most promising chemoprophy-
lactic activity was shown for two nanoformulations containing
the nonionic hydrophilic polymers PVP K30 and PVA.
4.2.2 Polymer-based RBC membrane nanomimics. An
ingenious strategy developed by Najer et al.116 consisted in
blocking the life cycle of the parasite by preventing the invasion
of host RBCs. For that purpose, nanostructures mimicking RBC
membranes, i.e. nanomimics, based on block copolymers with
heparin as a host cell receptor were built (Fig. 8a).
The design of nanomimics involved the initial synthesis of
two different block copolymers: poly(2-methyl-2-oxazoline)-
b l o c k -poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline)
(PMOXA-b-PDMS-b-PMOXA), which forms a polymersome, and
the PDMS–heparin block copolymer, with the chain of the
receptor heparin as a hydrophilic domain (Fig. 8b). Then, the
nanomimic 3D structure (Fig. 8c) was obtained by bulk rehy-
dration of a mixture of PMOXA-b-PDMS-b-PMOXA with 25%
(w/w) PDMS–heparin. The resulting self-assembled structure
exposed most of the heparin part outwards, making it acces-
sible to bind parasite ligands involved in the initial attachment
to host cells. These nanomimics have displayed a therapeutic
effect without the need for any other substance by blocking
invasion of host RBCs by the P. falciparum merozoite. Further-
more, they can also boost immune responses due to the
increased number of free merozoites circulating, thus acting
as vaccine adjuvants.
In a further study,117 the antimalarial activity of different
nanomimics constructed by varying the number or length of
heparin molecules on their surface was evaluated. Specifically,
their interaction with a well-known heparin-binding protein on
the surface of merozoites, P. falciparum merozoite surface
protein 1, was measured, showing high binding affinity. These
findings involving malaria parasite receptor molecules are very
relevant for the optimization of future nanomimic therapies for
infectious diseases.
4.2.3 Polymeric hydrogels. Polymeric hydrogels can be
defined as water-swollen polymeric materials that maintain a
distinct three-dimensional structure, which constitute the first
biomaterials designed for use in the human body.118 Several
methods for the preparation of polymeric hydrogels have been
explored and they can exhibit different morphologies including
slabs, microparticles, films and NPs.98 Various parameters
determine the degree of porosity of polymeric hydrogels, such
as the starting material or preparation method, which can
influence their bioactivity.
An example of using hydrogels as antimalarial nanocarriers
is the gum acacia-based hydrogels as a controlled dual-drug
delivery system for 4-aminoquinolines and curcumin.119
The drug release profile of this system showed dependence on
the degree of crosslinking of the hydrogel network and exhib-
ited different pharmacokinetics for both drugs, which
may contribute to overcoming undesirable drug resistance.
Another study developed by Aderibigbe120 comprised soy
Fig. 8 Polymer-based RBC membrane nanomimic concept and charac-
teristics: (a) schematic representation of the nanomimic concept. In step A,
fresh nanomimic structures (red circles) block merozoites (gray oval
structures) before they enter new RBCs (steps B, C, D, and E). (b) Chemical
structure of PMOXA-b-PDMS-b-PMOXA and PDMS–heparin, where
hydrophilic domains are colored in blue and hydrophobic cores in red.
(c) TEM and cryo-TEM images of the nanomimics; scale bars: 200 nm.
(a and c) reprinted (adapted) with permission from Najer et al.;116 copyright
(2014) American Chemical Society.
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protein isolate-carbopol-polyacrylamide-based hydrogels, which
exhibited pH sensitivity and were biodegradable after drug
release. In this case, the hydrogels were loaded with CQ dipho-
sphate and curcumin and their release mechanism was also
appropriate as dual drug delivery systems. More recently, Dawre
et al.121 formulated biodegradable hydrogels formed in situ
taking advantage of the rapid phase transition of lyotropic
liquid crystals in an environment that mimics intracellular
conditions. A mixture of oleic acid, dibutyl sebacate and poly-
sorbate 80 composed the lyotropic liquid crystalline preconcen-
trates, into which the antimalarials arteether and lumefantrine
were dissolved. The addition of the biodegradable copolymer
PLGA allowed a higher than threefold enhancement of
the hydrogel strength and sustained release of the drugs.
In addition, modified in vivo Peter’s four day suppressive
antimalarial assay122 and a clinical simulation study revealed
a rapid reduction in parasitemia levels with no recrudescence
and complete mice survival when using this efficacious thera-
peutic system.
4.2.4 Dendrimers. Dendrimers are monodisperse hyper-
branched polymers that present a high number of functional
moieties on their periphery leading to multivalency.
This feature, known as the ‘‘dendritic effect’’, can enhance
the properties associated with these moieties and was particu-
larly used as an advantage in nanomedicine.123 The unique
characteristics of dendrimers have been also exploited to
enhance the pharmacokinetic properties of antimalarial drugs.
In 2005, a poly-L-lysine (PLL) dendrimer (Fig. 9a) modified
with PEG was first employed to improve the solubility of
lipophilic artemether in water, boosting at the same time its
controlled release in vitro.124 Dendrimers coated with sugars,
commonly called glycodendrimers, were later used to encapsu-
late CQ and PQ. A galactose-coated polypropylene imine
dendrimer125 and galactose-coated PLL126 could encapsulate
PQ and CQ, respectively, enhancing their blood circulation
time in vitro and in vivo. Chondroitin sulfate A- and
PEG-coated PLL increased the stability of CQ in blood as well
as its circulation time in vivo.127 In all cases, the addition of
sugar moieties at the dendrimer’s periphery led to higher drug
encapsulation levels while reducing the toxicity of the
nanocarriers.
Dendrimers based on a biocompatible and biodegradable
2,2-bis(hydroxymethyl)propionic acid (bis-MPA) skeleton mod-
ified with glycine moieties at their periphery (Fig. 9a) have also
been used to encapsulate antimalarial drugs. Both single
macromolecules, i.e. dendronized hyperbranched molecules
(DHP) (Fig. 9b),128 and self-assembled amphiphilic structures,
i.e. hybrid dendritic–linear–dendritic block copolymers
(HDLDBC) (Fig. 9c) and Janus dendrimers, have been used.129
They all showed high drug loading capacities and excellent
Fig. 9 (a) PLL, bis-MPA and bis-GMPA dendritic structures, (b) DHP ‘‘single molecule’’ dissolution in water, and (c) amphiphilic HDLDBC based on
Pluronic F-127 and bis-MPA dendron self-assembly in water. Adapted from Movellan et al.129 and Martı́ Coma-Cros et al.128
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targeting towards pRBCs. Moreover, the amphiphilic
HDLDBCs, which are based on linear Pluronic F-127 and bis-
MPA dendrons, could enhance the activity of CQ and PQ
in vitro. A similar amphiphilic HDLDBC based on Pluronic
F-127 and a novel dendritic structure based on poly(esteramide)
2,2-bis(glycyloxymethyl)propionic acid (bis-GMPA in Fig. 9a)
has been described to encapsulate CQ, PQ and quinacrine.
It displayed high drug loading capacity and good targeting
towards pRBCs while showing a similar drug activity after
encapsulation.128
Artemisinin has been also covalently linked to 1st genera-
tion dendrimers leading to trimeric and tetrameric molecules.
The trimeric dendrimer showed a higher drug activity in vitro
than the free artesumic acid precursor and slightly lower than
free dihydroartemisinin, whereas the tetrameric dendrimer
exhibited a lower drug activity. The lower activity of the tetra-
meric dendrimer was related to its high lipophilicity, which
might limit its solubility in the culture media of malaria
parasites.130
4.3 Inorganic NPs
The research on NPs of inorganic composition as components
of potential treatments for malaria infection has received
increasing attention in recent years. However, it is still an area
that deserves further research in order to understand the
mechanism of action of different NPs and the stage of infection
in which they can be effective to prevent or cure malaria. Most
of the studies selected from recent years deal with NPs that
have active participation in the prevention or cure of malaria.
Such is the case of the metallic NPs and iron oxide NPs
described below. In addition, inorganic NPs of mesoporous
silica composition have been tested as effective carriers for
traditional antimalarial drugs.
4.3.1 Metallic NPs. The possibilities of action of metallic
NPs extend from attacking the mosquito vector to treating
malaria during the human infection cycle. Most metallic NPs
explored for these purposes are made of noble metals including
silver, gold and palladium, as extensively reviewed in Rahman
et al.10 and Barabadi et al.11 In particular, silver has shown good
antibacterial properties due to the release of Ag+ ions, which
likely interact with thiol and phosphate groups in proteins and
DNA. This interaction disrupts the cell wall integrity, impairing
essential enzymes, inactivating bacterial DNA and RNA or
binding subcellular components.131 The broad-spectrum anti-
microbial activity of silver has also been explored against
malaria, and this, together with the unique properties of its
nanostructured form, has opened ways for malaria treatments
based on silver NPs (AgNPs) against different stages of the
infection, in both the mosquito and human hosts.132 As for the
former, a crucial issue for their application is the possible
ecological damage when used to replace classical synthetic
insecticides. In this respect, there are many studies that indi-
cate their innocuity for non-target aquatic microorganisms.132
As for toxicity for human hosts, the influence of the AgNP size
on the biocompatibility is known. Sizes larger than 200 nm
accumulate in the liver and spleen. Nevertheless, toxicity in
humans seems to come from the release of the ionic form of
silver rather than from the nanoparticulate form of silver metal,
as reviewed by Rai et al.132
The activity of AgNPs is greatly influenced by their morpho-
logical and physical features such as, among others, size, shape
and aggregation propensity. Although the control of these
aspects during synthesis is not yet fully mastered, the benefits
of biological processes to prepare AgNPs are broadly accepted.
Indeed, the synthesis of metal NPs from plant extracts has
become an eco-friendly and cost-effective process, and provides
different types of reducing and capping agents to yield stable
AgNPs. A comprehensive review by Benelli et al. gathers the
biosynthesis of NPs from plant extracts, and how this type of
process brings the great potential of such nanosystems to the
fight against the vectors of many infectious diseases such as
malaria.133 An important aspect of this research is that differ-
ent plants can be classified as reducing and capping agents to
prepare active metal NPs. A significant amount of work has
been done in India to develop medical products from Indian
medicinal plants, including nanotechnology-based ones.
Mosquitocidal activity of metallic NPs has been described at
different stages of the insect’s life cycle with increased pesticide
efficacy compared to plant-based preparations. Thus, the half
lethal concentration, LC50, of synthesized AgNPs estimated
for eggs, larvae, pupae and adults has been found to be between
1 and 40 mg ml1, which is a much lower value than that
observed for the corresponding plant extracts.133 AgNPs have
been mainly applied as larvicides but are also active as ovicides,
adulticides, and pupicides. It is important to remark that they
do not show toxicity for non-target organisms.134 Other effects
of AgNPs are to reduce mosquito longevity and fecundity as well
as to act as a lure and kill approach. This has been observed for
AgNPs synthesized from a plant that provides capping with
metabolites that are attractive for a kind of mosquito.135
In addition to Ag, other metal compositions including Au, Pd,
Co, Ni, Cu and also ZnO and TiO2 have shown toxicity against
the mosquito larval stage, features that could be conveniently
exploited to prevent malaria.11
The utilization of noble metal-based NPs as antimalarial
agents has been less described. Leaf extracts of Andrographis
paniculata allowed the synthesis of AgNPs with diameter
around 55 nm, which showed antiplasmodial activity.136 More
recently, the same authors described the great potential of fern
extracts from Indian plants to synthesize AgNPs with promising
inhibitory activity against CQ-resistant P. falciparum.137
Similarly to AgNPs, biosynthetic procedures from leaf
extracts also permitted the synthesis of PdNPs that decreased
significantly (by 78%) the parasite growth in mice infected with
P. berghei, with a half maximal inhibitory concentration (IC50)
value of 16.44 mg Kg1 body weight.138 With respect to the
synthesis, leaf aqueous extracts of Eclipta prostrata were
employed, providing a green and cheap process to prepare
PdNPs stable in solution with an average size of 27 nm and
promising antimalarial activity.
Au-N-LK3 AuNPs with sizes between 5 and 50 nm and
prepared from the marine actinobacteria Streptomyces spp.
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delayed parasitemia by 6% at day 8 of infection, and increased
survival from 50 to 85% in in vivo experiments with P. berghei-
infected mice.139 The role attributed to Au-N-LK3 is related to
the response of the organism to parasite infection, helping to
regulate the presence of blood factors that play an important
role in the immune response to malaria infection. In particular,
the development of severe malaria alters the concentration of
TNF-a (tumor necrosis factor a) and TGF-b1 (transforming
growth factor-b1). In a similar way to CQ, Au-N-LK3 inhibits
the production of TNF-a, whose concentration increases in
blood upon infection.
4.3.2 Iron oxide NPs. Non-toxic iron oxide NPs, IONPs,
have been successfully employed as a reservoir of ferrous ions
(Fe2+), which can improve the activity of ATS. The mechanism
of action of this drug relies on its endoperoxide bond, the
cleavage of which is catalyzed by Fe2+. This dependence deter-
mines the specificity of ATS and artemisinin derivatives
towards infected RBCs. Indeed, cleavage of endoperoxide
bonds provides reactive oxygen species that cause irreversible
damage to parasite DNA and proteins. Kannan et al. have
recently reported promising results with Fe3O4 NPs coated with
2-aminoterphthalic acid, ATA-IONPs, which provide sustained
release of Fe2+ ions in a pH-dependent manner.140 Low pH
favors the slow conversion of Fe3+ to Fe2+, which activates ATS.
Interestingly, such low pH is encountered in the interior of
the parasite food vacuole and this favors the specificity of such
ATA-IONP-fortified ATS towards Plasmodium during the tropho-
zoite stage (Fig. 10). These results provide the possibility of
overcoming problems related to artemisinin-resistant malaria
parasites. Furthermore, in vivo studies in P. berghei-infected
mice showed that a tenfold lower dose compared to free ATS
was enough to decrease parasitemia by 80% on day 7 of
infection. A combination of 30 mg Kg1 ATS and 5 mg Kg1
ATA-IONPs showed the same antimalarial action as 60 mg Kg1
of the free drug.
4.3.3 Mesoporous silica NPs. Mesoporous silica NPs
(MSNs) have demonstrated good potential as nanocarriers for
drug delivery due to their properties related to high loading
capacity, scalable synthesis, adjustable pore size and volume,
high intracellular uptake, thermal stability and excellent
biocompatibility.141,142 Amolegbe et al. have studied the
potential of mesoporous MCM-41 as a carrier for antimalarial
drugs.143,144 MCM-41 is a silicate/aluminosilicate mesoporous
molecular sieve synthesized by Beck et al. using liquid crystal
templates.145 With the aim of improving bioavailability, unmo-
dified MCM-41 and MCM-41 pore-functionalized with either
amino (aMCM-41) or phenyl groups (pMCM-41) were tested to
encapsulate ATS, a drug with a short half-life in blood,143 and
QN, a lipophilic drug that can cause severe adverse effects at
therapeutic doses.144 The interactions between MSNs and the
drug determined the release profile, whereby aMCM-41 showed
slow release of ATS due to hydrogen-bonding interactions
between the amino groups in the MSNs and the ATS carboxylic
group. Such slow release of the drug can make these MSNs also
interesting for oral administration.143 Regarding QN, the func-
tionalization of pMCM-41 with phenyl rings appeared as a useful
strategy to increase the drug loading capacity and give better
controlled release.144 Both systems were tested in vitro against
P. falciparum and in vivo against P. berghei-infected mice.144
The in vitro results showed the best activity for unmodified
MSNs encapsulating QN, MCM-41/QN, whereas amino-
modified aMCM-41/ATS was found to be inactive. However,
the best in vivo results were found for both the unmodified
MCM-41/QN and aMCM-41/ATS systems. MCM41/QN showed
the highest effectiveness in delivering the drug to the target cells with
ED50 (effective dose causing 50% inhibition) o 0.0625 mg Kg1
body weight, and an acceptable mean survival time.
4.4 Miscellaneous
This section includes some other recently explored molecular
platforms that, although they do not fit within the previous
classification, have shown interesting antimalarial properties
either on their own or acting as antimalarial drug carriers and
hence their use is considered promising for future malaria
therapeutic strategies.
4.4.1 Graphene. The dense 2D-structure and chemical,
electrical and mechanical properties of graphene and graphene
oxide have fostered their application in wearable fabrics that
may include functionalities such as sensing, temperature con-
trol, energy storage or water-vapor transmission, and elasticity
compatible with stretchable fabrics.146 Hurt et al. have explored
these properties to include graphene-based films in fabrics in
order to make them resistant to mosquito biting, thus preventing
infectious diseases transmitted through such vectors.147 Under
dry conditions, graphene oxide (GO) and reduced graphene
oxide (rGO) are protective against mosquito biting because
of their molecular barrier properties that make fabrics
impermeable to skin-associated molecular attractants. Under
wet conditions, e.g. sweat, this molecular barrier loses effective-
ness but rGO still maintains its mechanical properties,
preventing mosquito puncturing. In contrast, the hydrophilic
Fig. 10 Confocal microscopy was used to explore the localization of
fluorescein-labeled ATA-IONPs, which appear in green within the food
vacuole compartment of Plasmodium marked by LysoTracker Red.
The nucleus of Plasmodium is labeled by Hoechst in blue. Figure reprinted
(adapted) with permission from Kannan et al.;140 copyright (2019) Elsevier.
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nature of the oxygen-containing groups in GO favors the
formation of a hydrogel upon wetting, which facilitates mos-
quito sting penetration.
Due to its excellent biocompatibility,148 GO has also been
explored for its active role in preventing RBC infection by
Plasmodium. Lim et al. have proposed a two-pronged action
mechanism of GO nanosheets, which are able to inhibit signifi-
cantly the invasion of RBCs by P. falciparum parasites.149 First, GO
nanosheets constitute a physical barrier against parasite infec-
tion by capturing merozoites present in blood, thus impeding
their adhesion to RBCs. Second, electrostatic and p–p interac-
tions impart GO nanosheets with a strong affinity for many
biomolecules, among which are the nutrients required for para-
site growth; their removal from blood delays the intraerythrocytic
maturation of Plasmodium, and hence reduces its viability.
4.4.2 Cyclodextrin complexes. Cyclodextrins (CD) are cyclic
oligosaccharides formed from glucose units that are highly
biocompatible, interact with a wide range of molecules and
biomolecules and are susceptible to easy functionalization to
tune specific interactions. These features make them highly
promising platforms for biomedical applications.150 Native
CDs, namely those natural products formed by 6, 7 and 8
glucoses, a-CD, b-CD, and g-CD, respectively, as well as modified
CDs, some of them already approved for human use, e.g.
2-hydroxypropyl-b-cyclodextrin (2-HP-b-CD), have been explored
to develop medical treatments for infectious diseases including
malaria. For instance, anionic CDs with sulfate groups have
proven successful to inhibit P. falciparum growth and to reduce
parasitemia in P. berghei-infected mice, which correlated with the
degree of sulfate functionalization.151 Nevertheless, the ability of
CDs to form soluble complexes with low water-soluble molecules
provides an interesting strategy to investigate novel treatments
against malaria based on the improved oral bioavailability of
already known lipophilic antimalarials.4 Microparticles of arte-
misinin/b-CD complexes formed by spray drying provided
agglomerates suitable for oral administration. The interaction
with b-CD increased six-fold the solubility of artemisinin relative
to the free drug, and hence its oral bioavailability, as demon-
strated in in vivo experiments in rats.152 Unlike artemisinin, for
which the formation of inclusion drug/CD complexes was not
fully confirmed, and depended on the drug/b-CD ratio,152 arte-
mether has been reported to form stable inclusion complexes
with 2-HP-b-CD with high entrapment efficiency, which increased
its solubility.153 In vivo studies in rats showed that the intragastric
administration of the complex resulted in faster blood absorption
and bioavailability than for the free drug.
5 Future perspectives and conclusions
After one hundred years of using classical therapeutic (drugs)
and prophylactic (vaccines) approaches that have not suc-
ceeded in eradicating malaria, nanotechnology and nano-
materials can offer new opportunities to build customized tools
for prophylactic and therapeutic purposes that bring new
solutions in different stages of malaria pathophysiology.
Issues concerning drug solubility, biostability, toxicity and
uncontrolled pharmacokinetics can be overcome with adequately
designed drug NCs based on liposomes, polymers or dendrimers.
Furthermore, drug resistance evolves when one cannot deliver to
the parasites a sufficiently high dose to kill them rapidly. This
happens more easily when the drug is not specifically targeted to
the pathogen and therefore it distributes throughout the body,
which imposes a maximum overall dose that does not trigger
undesirable side effects. NCs carrying binding molecules for
specific receptors present only on cells infected by the malaria
parasite, represent a highly promising option.
For most malaria cases, to be treated in endemic regions
with poor or inexistent healthcare infrastructure, and in order
to favor patient compliance, oral delivery will be the preferred
option and polymer-based NCs can be made apt for this.
However, for severe malaria cases where the patient is usually
hospitalized, or in other contexts such as in a future malaria
eradication campaign where the disease will be entrenched in
small contained areas, intravenous administration can be
reasonably considered. In these cases, liposomal NCs are an
interesting alternative since they have a long track record of
successful clinical applications in a wide variety of diseases.
Targeting specificity to infected cells is a key issue that can
be also faced with NCs. Since they can operate at the molecular
level, nanomaterials can be more precise in reaching a parti-
cular drug target, or they can be designed to present several
antigens to immune cells for the production of a new genera-
tion of better vaccines.
Another possibility for prevention is attacking the mosquito
vector. In this respect, mainly metal-based NPs but also
liposome-based ones have been shown to be successful to
prevent malaria infection.
The main concern when using nanomaterials is related to
their production cost, which is an issue to consider when dealing
with pathologies like malaria, where the vast majority of cases are
in poverty-ridden areas. Pathologies that are not prominent in
high income regions have little chance of attracting industrial
interest since the large investment in product development will
not be recovered as easily as when selling drugs to treat carcino-
mas, Alzheimer’s disease or obesity. However, severe malaria is
such a serious life-threatening condition and eradication is such
a long sought-after goal that in these cases arguing economic
reasons would be out of place. Examples of ways to overcome this
obstacle exist, such as the current commitment of a few big
pharma companies to devote part of their budget to infectious
disease research, but more public and private economic efforts
are needed. Some of the basic research results obtained in this
field are highly promising, but it is necessary to capture the
interest of clinicians and establish collaborations with the med-
ical sector in order to adapt this new technology to the require-
ments of its deployment as a treatment for people.
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